NXTC
NextCure, Inc.
$2.08
-6.95%
$7.5M
No data for this timeframe.
Vol
Market Cap$7.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders9 funds
Inst. Value$3.3M
Inst. Activity1 buys / 0 sells
SEC Reports4
Press Releases4
Recent Activity
Jun 1, 2026
SEC
NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, showing a 55% ORR in
8-K — Impact 6/10
Jun 1, 2026
fda
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
<p>BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Track
May 7, 2026
SEC
NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with
8-K — Impact 3/10
Apr 24, 2026
SEC
NextCure, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on the elect
DEFA14A — Impact 3/10
Jan 30, 2026
Insider
Cobourn Steven P. was granted 14,670 shares
Chief Financial Officer
Jan 30, 2026
Insider
Richman Michael was granted 38,190 shares
President & CEO
Jan 30, 2026
Insider
Mayer Timothy was granted 14,670 shares
Chief Operating Officer
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
60,534 shares ($646.5K)
Price Targets
$19.33
+831.7% upside
Strong Buy
Current $2.08
Low $15.00
Median $18.00
High $25.00
3 analysts
$15.00
$25.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.92 ▼ -4.3% | $-2.03 — $-1.84 | 83% YoY | 3 |
| Next Q | $-1.77 ▲ +9.7% | $-2.05 — $-1.30 | 45% YoY | 3 |
| Current FY | $-7.32 ▲ +4.8% | $-8.11 — $-6.17 | 63% YoY | 3 |
| Next FY | $-8.31 ▼ -8.3% | $-10.41 — $-5.49 | -13% YoY | 3 |
Latest Reports
BULLISH
8-K
6/10
NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, showing a 55% ORR in
Jun 1, 2026
BULLISH
Press
7/10
NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55%
Jun 1, 2026
NEUTRAL
8-K
3/10
NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | — |
| RENAISSANCE TECHNOLOGIES LLC | $646.5K | ADD |
| BlackRock, Inc. | $296.8K | — |
| Woodline Partners LP | $293.7K | — |
| VANGUARD FIDUCIARY TRUST CO | $168.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 30, 2026 | Cobourn Steven | A | $0.00 |
| Jan 30, 2026 | Richman Michael | A | $0.00 |
| Jan 30, 2026 | Mayer Timothy | A | $0.00 |
| Jan 30, 2026 | Guha Udayan | A | $0.00 |
| Jan 30, 2026 | Kundu Sourav | A | $0.00 |
9 institutional holders with $3.3M total value (313,298 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, BlackRock,. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 160,473 | $1.7M | 50.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 60,534 | $646.5K | 19.5% | ADD +80.0% |
| 3 | BlackRock, Inc. | 27,793 | $296.8K | 9.0% | — |
| 4 | Woodline Partners LP | 27,498 | $293.7K | 8.9% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 16,015 | $168.5K | 5.1% | — |
| 6 | CITADEL ADVISORS LLC | 15,292 | $160.9K | 4.9% | NEAR_EXIT -80.6% |
| 7 | BARCLAYS PLC | 5,626 | $60.1K | 1.8% | — |
| 8 | MORGAN STANLEY | 66 | $705.00 | 0.0% | — |
| 9 | CITIGROUP INC | 1 | $11.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 33,634 | 60,534 | +80.0% | $646.5K | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 67,983 | 91,910 | +35.2% | $1.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 23 | 173 | +652.2% | $2.5K | 2025-Q4 |
| UBS Group AG | ADD | 8,537 | 12,299 | +44.1% | $5.7K | 2025-Q2 |
| DIMENSIONAL FUND ADVISORS LP | NEAR_EXIT | 85,853 | 12,175 | -85.8% | $5.8K | 2025-Q1 |
| UBS Group AG | DOUBLED | 4,202 | 8,537 | +103.2% | $4.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 406,000 | 519,300 | +27.9% | $400.4K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 5,390 | 252 | -95.3% | $194.00 | 2024-Q4 |
| Hudson Bay Capital Management LP | TRIM | 203,800 | 107,672 | -47.2% | $147.5K | 2024-Q3 |
| Assenagon Asset Management S.A. | TRIM | 184,486 | 85,308 | -53.8% | $116.9K | 2024-Q3 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 289,050 | 55,954 | -80.6% | $76.7K | 2024-Q3 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | Cobourn Steven P. | Chief Financial Officer | AWARD | 14,670 | — | — |
| Jan 30, 2026 | Richman Michael | President & CEO | AWARD | 38,190 | — | — |
| Jan 30, 2026 | Mayer Timothy | Chief Operating Officer | AWARD | 14,670 | — | — |
| Jan 30, 2026 | Guha Udayan | Chief Medical Officer | AWARD | 14,670 | — | — |
| Jan 30, 2026 | Kundu Sourav | Sr VP, Dev. & Mfg. | AWARD | 8,270 | — | — |
| Jan 30, 2026 | Shaw Kevin G. | Sr VP, General Counsel | AWARD | 8,270 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
BULLISH
8-K
6/10
NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, s
Jun 1, 2026
NEUTRAL
8-K
3/10
NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash
May 7, 2026
NEUTRAL
DEFA14A
3/10
NextCure, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders wi
Apr 24, 2026
NEUTRAL
8-K
5/10
NextCure reported its full year 2025 financial results, showing a net loss of $55.8 million, a sligh
Mar 5, 2026
BULLISH
7/10
NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO
Jun 1, 2026
NEUTRAL
4/10
NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-res
May 4, 2026
NEUTRAL
4/10
NextCure announced that Phase 1 data for SIM0505, an investigational antibody-drug conjugate targeti
Apr 21, 2026
NEUTRAL
5/10
NextCure provided a business update and reported full-year 2025 financial results, highlighting anti
Mar 5, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.33 mean target
+831.7% upside
Strong Buy (1.33)
$15.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $2.08 |
| Target Low | $15.00 |
| Target Mean | $19.33 |
| Target Median | $18.00 |
| Target High | $25.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.92 | $-2.03 | $-1.84 | 83.0% | -4.3% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-1.77 | $-2.05 | $-1.30 | 45.0% | +9.7% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-7.32 | $-8.11 | $-6.17 | 62.7% | +4.8% | 2↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-8.31 | $-10.41 | $-5.49 | -13.5% | -8.3% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.920 | |
| 7d ago | $-1.865 | -0.055 |
| 30d ago | $-1.840 | -0.080 |
| 60d ago | $-2.000 | +0.080 |
| 90d ago | $-2.000 | +0.080 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
fda
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
<p>BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KDW0m2lgf3uIqKzn7QcrIJuyWmxCesvDs0NldZThK4
May 7, 2026
earnings
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
<p>BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Eqod-6U2x2h9yL5PHSkUGmxXOejC9FfnghBi7fAOjJ
May 4, 2026
fda
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
<p>BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KoHgS0Tvm5Mfje1Jpk49YUqgPN0kPbhZuR5-sGEaNPQ
Apr 29, 2026
earnings_calendar
NXTC Q1 2026 Earnings Scheduled — 2026-04-29
Apr 21, 2026
fda
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 <pre>Poster to be presented at the American Society for C
Apr 7, 2026
other
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
<p>BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=JTrhxTq3XyZDgJuypnsGs3ZXqT-Unsp4-Msr_9brl
Mar 5, 2026
announcement
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
<p>BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=t7Is3x6u0WekRf_isez_1BVqzul_u2JMQDXHI0CIe
Mar 4, 2026
earnings_calendar
NXTC Q4 2025 Earnings After Market Close — 2026-03-04